327 related articles for article (PubMed ID: 23283305)
1. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.
Chung S; Suzuki H; Miyamoto T; Takamatsu N; Tatsuguchi A; Ueda K; Kijima K; Nakamura Y; Matsuo Y
Oncotarget; 2012 Dec; 3(12):1629-40. PubMed ID: 23283305
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.
Chung S; Kijima K; Kudo A; Fujisawa Y; Harada Y; Taira A; Takamatsu N; Miyamoto T; Matsuo Y; Nakamura Y
Oncotarget; 2016 Apr; 7(14):18171-82. PubMed ID: 26918358
[TBL] [Abstract][Full Text] [Related]
3. [
Hu F; Gong C; Gai Y; Jiang D; Liu Q; Wang S; Hu M; Pi R; Shu H; Hu J; Lan X
Mol Pharm; 2021 Sep; 18(9):3544-3552. PubMed ID: 34482695
[TBL] [Abstract][Full Text] [Related]
4. A novel carbon-11 radiolabeled maternal embryonic leucine zipper kinase inhibitor for PET imaging of triple-negative breast cancer.
Tang R; Gai Y; Li K; Hu F; Gong C; Wang S; Feng F; Altine B; Hu J; Lan X
Bioorg Chem; 2021 Feb; 107():104609. PubMed ID: 33454507
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia.
Zhang Y; Zhou X; Li Y; Xu Y; Lu K; Li P; Wang X
Oncogene; 2018 Oct; 37(41):5520-5533. PubMed ID: 29895969
[TBL] [Abstract][Full Text] [Related]
6. Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.
Maes A; Maes K; Vlummens P; De Raeve H; Devin J; Szablewski V; De Veirman K; Menu E; Moreaux J; Vanderkerken K; De Bruyne E
Blood Cancer J; 2019 Nov; 9(12):87. PubMed ID: 31740676
[TBL] [Abstract][Full Text] [Related]
7. The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor.
Cho YS; Kang Y; Kim K; Cha YJ; Cho HS
Biochem Biophys Res Commun; 2014 Apr; 447(1):7-11. PubMed ID: 24657156
[TBL] [Abstract][Full Text] [Related]
8. MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363
[No Abstract] [Full Text] [Related]
9. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.
Hikichi Y; Honda K; Hikami K; Miyashita H; Kaieda I; Murai S; Uchiyama N; Hasegawa M; Kawamoto T; Sato T; Ichikawa T; Cao S; Nie Z; Zhang L; Yang J; Kuida K; Kupperman E
Mol Cancer Ther; 2012 Mar; 11(3):700-9. PubMed ID: 22188812
[TBL] [Abstract][Full Text] [Related]
10. Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in osteosarcoma.
Jeddo SFA; Wei X; Li K; Li X; Yang Q; Dongol S; Li J
Oncol Rep; 2020 Sep; 44(3):1037-1048. PubMed ID: 32705239
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells.
Kato T; Inoue H; Imoto S; Tamada Y; Miyamoto T; Matsuo Y; Nakamura Y; Park JH
Oncotarget; 2016 Apr; 7(14):17652-64. PubMed ID: 26933922
[TBL] [Abstract][Full Text] [Related]
12. MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors.
Meel MH; Guillén Navarro M; de Gooijer MC; Metselaar DS; Waranecki P; Breur M; Lagerweij T; Wedekind LE; Koster J; van de Wetering MD; Schouten-van Meeteren N; Aronica E; van Tellingen O; Bugiani M; Phoenix TN; Kaspers GJL; Hulleman E
Neuro Oncol; 2020 Jan; 22(1):58-69. PubMed ID: 31504799
[TBL] [Abstract][Full Text] [Related]
13. MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
Kohler RS; Kettelhack H; Knipprath-Mészaros AM; Fedier A; Schoetzau A; Jacob F; Heinzelmann-Schwarz V
Gynecol Oncol; 2017 Apr; 145(1):159-166. PubMed ID: 28214016
[TBL] [Abstract][Full Text] [Related]
14. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
Inoue H; Kato T; Olugbile S; Tamura K; Chung S; Miyamoto T; Matsuo Y; Salgia R; Nakamura Y; Park JH
Oncotarget; 2016 Mar; 7(12):13621-33. PubMed ID: 26871945
[TBL] [Abstract][Full Text] [Related]
15. MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies.
Pitner MK; Taliaferro JM; Dalby KN; Bartholomeusz C
Expert Opin Ther Targets; 2017 Sep; 21(9):849-859. PubMed ID: 28764577
[TBL] [Abstract][Full Text] [Related]
16. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
Huang M; Huang Y; Guo J; Yu L; Chang Y; Wang X; Luo J; Huang Y; Tu Z; Lu X; Xu Y; Zhang Z; Zhang Z; Ding K
Eur J Med Chem; 2021 Feb; 211():113023. PubMed ID: 33248853
[TBL] [Abstract][Full Text] [Related]
17. Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma.
Bolomsky A; Heusschen R; Schlangen K; Stangelberger K; Muller J; Schreiner W; Zojer N; Caers J; Ludwig H
Haematologica; 2018 Feb; 103(2):325-335. PubMed ID: 29122991
[TBL] [Abstract][Full Text] [Related]
18. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1/S cell cycle arrest via the ATM/CHK2/p53 pathway.
Chen S; Zhou Q; Guo Z; Wang Y; Wang L; Liu X; Lu M; Ju L; Xiao Y; Wang X
J Cell Mol Med; 2020 Jan; 24(2):1804-1821. PubMed ID: 31821699
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
Simon M; Mesmar F; Helguero L; Williams C
PLoS One; 2017; 12(2):e0172832. PubMed ID: 28235006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
